| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.05 M USD | -7.82 M USD | -8.31 M USD | -7.74 M USD | -4.37 M USD | -508710 USD |
| Depreciation & Amortization | 74182 USD | 75618 USD | 648708 USD | 156598 USD | 145719 USD | 157039 USD |
| Stock-Based Compensation | 6 USD | 20094 USD | 189245 USD | 433004 USD | 68458 USD | 3730 USD |
| Capital Expenditures | 173735 USD | 306783 USD | 704166 USD | 1.20 M USD | 23947 USD | — |
| Cash Flow from Investing | -173735 USD | -306783 USD | -704166 USD | -1.20 M USD | -23947 USD | — |
| Cash Flow from Financing | 7.09 M USD | 10.22 M USD | 1.11 M USD | 8075 USD | 22.53 M USD | 1.33 M USD |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -6.23 M USD | -8.13 M USD | -9.02 M USD | -8.94 M USD | -4.39 M USD | — |
Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings. The company specializes in minimally invasive point-of-care tests and devices designed to provide timely, lab-quality biomarker results near the patient, supporting faster clinical decision-making in critical care environments. Its flagship Symphony platform is a near-patient biomarker detection system aimed at conditions where early and precise measurement of inflammatory and infectious markers can guide treatment. Bluejay Diagnostics primarily targets the infectious disease, inflammation, and oncology markets, working to enable more efficient triage and monitoring of patients in emergency departments, intensive care units, and other acute-care settings. Headquartered in Acton, Massachusetts and founded in 2015, the company operates within the health technology sector and the medical specialties industry, serving healthcare providers seeking to streamline workflows and improve access to actionable diagnostic information at or near the point of care.